^
    Back
    Association details:
    Biomarker:TNFRSF8 overexpression
    Cancer:Hodgkin Lymphoma
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    Adcetris (brentuximab vedotin) (Microtubule inhibitor, CD30-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Blood
    Title:

    Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results

    Published date:
    04/07/2021
    Excerpt:
    This phase 1-2 study evaluated brentuximab vedotin (BV) combined with nivolumab (Nivo) as first salvage therapy in patients with relapsed or refractory classical Hodgkin lymphoma. Median gene expression of CD30 in tumors was higher in patients who responded compared with those who did not. Longer-term follow up of BV and Nivo as a first salvage regimen shows durable efficacy and impressive PFS...
    DOI:
    10.1182/blood.2020009178
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Blood
    Title:

    Baseline Tumor Transcriptome Characteristics Associated with the Response of Relapsed/Refractory Hodgkin Lymphoma Patients to Brentuximab Vedotin in Combination with Nivolumab

    Published date:
    11/01/2018
    Excerpt:
    Baseline tumor expression of CD30 above 16 counts per million mapped reads (CPM) was strongly associated with achieving CR after BV+Nivo (65% sensitivity and 93% specificity). CRs were associated with several other factors, including higher baseline tumor expression of macrophage markers CD14 and CD163 and lower expression of the Nivo target PD-1 (PDCD1) and multidrug resistance-associated protein 2 (MRP2/ABCC2) in the tumor microenvironment.
    DOI:
    10.1182/blood-2018-99-115481
    Trial ID:
    NCT02572167